MSD, a company with over 40 years of legacy in research and innovation for preventing pneumococcal diseases, has announced the launch of a new innovative pneumococcal conjugate vaccine in Greece aimed at the adult population. This vaccine is designed to target 21 serotypes, which cover the majority of invasive pneumococcal disease in adults, and it uniquely includes eight serotypes that are not targeted by any other pneumococcal vaccine available.

The introduction of this pneumococcal conjugate vaccine is particularly significant for unvaccinated adult patients, especially the elderly and those in high-risk groups due to underlying health conditions that put them at considerable risk for pneumococcal pneumonia and invasive pneumococcal disease. The vaccine offers the potential for significant benefits by providing coverage for these unique serotypes, which may help in reducing the incidence of severe health outcomes associated with pneumococcal infections.

With this initiative, MSD and BIANEX are taking an active role in promoting protection for the adult population over the age of 65, reflecting an important public health strategy in Greece. Through their collaboration, they aim to enhance immunization efforts and ultimately improve health outcomes for vulnerable groups in society, emphasizing the importance of vaccination in preventing serious diseases like pneumococcal pneumonia.